Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Tuija Väänänen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Möttönen, Pekka Hannonen, Markku Korpela, Markku J. Kauppi, Kari Laiho, Oili Kaipiainen-Seppänen, Riitta Luosujärvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen

    Research output: Contribution to journalArticleScientificpeer-review

    35 Citations (Scopus)
    Original languageEnglish
    Article numbere0183294
    Pages (from-to)e0183294
    JournalPLoS ONE
    Volume12
    Issue number8
    DOIs
    Publication statusPublished - 2017
    Publication typeA1 Journal article-refereed

    Publication forum classification

    • Publication forum level 1

    Cite this